Barriers and Facilitators to DATA Waivered Providers Prescribing Buprenorphine: A Qualitative Analysis Applying the Theory of Planned Behavior

References

• Ajzen, I., & Fishbein, M. (1980). Understanding attitudes and predicting social behaviour. Englewood cliffs, NJ: Prentice-Hall.
   Google Scholar
• Ajzen, I. (1985). From intentions to actions: A theory of planned behavior. In Action control (pp. 11–39). https://doi.org/10.1007/978-3-642-69746-3_2
   Google Scholar
• Ajzen, I. (2006). Constructing a TpB questionnaire. https://people.umass.edu/aizen/pdf/tpb.measurement.pdf
   Google Scholar
• Ajzen, I. (1991). The theory of planned behavior. Organizational Behavior and Human Decision Processes, 50(2), 179–211. https://doi.org/10.1016/0749-5978(91)90020-T
   Google Scholar
• Andrilla, C. H. A., Moore, T. E., Patterson, D. G., & Larson, E. H. (2019). Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: A 5‐year update. The Journal of Rural Health: Official Journal of the American Rural Health Association and the National Rural Health Care Association, 35(1), 108–112.
   PubMed Web of Science ®Google Scholar
• Bach, P., & Hartung, D. (2019). Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders. Addiction Science & Clinical Practice, 14(1), 30. https://doi.org/10.1186/s13722-019-0158-0
   PubMed Web of Science ®Google Scholar
• Bachhuber, M. A. (2020). How do state Medicaid programs determine what substance use disorder treatment medications need prior authorization? An overview for clinicians. Addiction Science & Clinical Practice, 15(1), 20. https://doi.org/10.1186/s13722-020-00194-7
   PubMed Web of Science ®Google Scholar
• Barry, D. T., Irwin, K. S., Jones, E. S., Becker, W. C., Tetrault, J. M., Sullivan, L. E., Hansen, H., O’Connor, P. G., Schottenfeld, R. S., & Fiellin, D. A. (2009). Integrating buprenorphine treatment into office-based practice: a qualitative study [Comparative Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Journal of General Internal Medicine, 24(2), 218–225. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med6&AN=19089500 https://doi.org/10.1007/s11606-008-0881-9
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. (2022). Death Rate Maps & Graphs. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Retrieved June 27, from https://www.cdc.gov/drugoverdose/deaths/index.html
   Google Scholar
• Cernasev, A., Desselle, S., Hohmeier, K. C., Canedo, J., Tran, B., & Wheeler, J. (2021). Pharmacy technicians, stigma, and compassion fatigue: Front-line perspectives of pharmacy and the US opioid epidemic. International Journal of Environmental Research and Public Health, 18(12), 6231. https://doi.org/10.3390/ijerph18126231
   PubMed Web of Science ®Google Scholar
• Clark, R. E., Baxter, J. D., Barton, B. A., Aweh, G., O’Connell, E., & Fisher, W. H. (2014). The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence. Health Services Research, 49(6), 1964–1979. https://doi.org/10.1111/1475-6773.12201
   PubMed Web of Science ®Google Scholar
• Connery, H. S. (2015). Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harvard Review of Psychiatry, 23(2), 63–75. https://doi.org/10.1097/HRP.0000000000000075
   PubMed Web of Science ®Google Scholar
• DeFlavio, J. R., Rolin, S. A., Nordstrom, B. R., & Kazal, L. A.Jr. (2015). Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians [Review]. Rural & Remote Health, 15, 3019. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med8&AN=25651434
   PubMed Web of Science ®Google Scholar
• Friese, S. (2014). Qualitative data analysis with ATLAS. ti. Sage.
   Google Scholar
• Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., Ling, W., Malkerneker, U., McNicholas, L., Renner, J., Stine, S., & Tusel, D. (2003). Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine, 349(10), 949–958. https://doi.org/10.1056/NEJMoa022164
   PubMed Web of Science ®Google Scholar
• GetWaiveredTX. (2020). Retrieved August 10, 2019, from https://www.getwaiveredtx.com/about/
   Google Scholar
• Ghertner, R. (2019). US trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018. Drug and Alcohol Dependence, 204, 107527. https://doi.org/10.1016/j.drugalcdep.2019.06.029
   PubMed Web of Science ®Google Scholar
• Giguere, A. M., Labrecque, M., Haynes, R. B., Grad, R., Pluye, P., Légaré, F., Cauchon, M., Greenway, M., & Carmichael, P.-H. (2014). Evidence summaries (decision boxes) to prepare clinicians for shared decision-making with patients: a mixed methods implementation study. Implementation Science, 9(1), 144. https://doi.org/10.1186/s13012-014-0144-6
   PubMedGoogle Scholar
• Glanz, K., Rimer, B. K., & Viswanath, K. (2008). Health behavior and health education: theory, research, and practice. John Wiley & Sons.
   Google Scholar
• Gordon, A. J., Kavanagh, G., Krumm, M., Ramgopal, R., Paidisetty, S., Aghevli, M., Goodman, F., Trafton, J., & Liberto, J. (2011). Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychology of Addictive Behaviors: Journal of the Society of Psychologists in Addictive Behaviors, 25(2), 215–224. http://ovidsp.ovid.com/ovidweb.cgi?T = JS&CSC = Y&NEWS = N&PAGE = fulltext&D = med7&AN=21480679
   PubMed Web of Science ®Google Scholar
• Haffajee, R. L., Lin, L. A., Bohnert, A. S., & Goldstick, J. E. (2019). Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder. JAMA Network Open, 2(6), e196373–e196373. https://doi.org/10.1001/jamanetworkopen.2019.6373
   PubMed Web of Science ®Google Scholar
• Hennink, M. M., Kaiser, B. N., & Weber, M. B. (2019). What influences saturation? Estimating sample sizes in focus group research. Qualitative Health Research, 29(10), 1483–1496.
   PubMed Web of Science ®Google Scholar
• Hill, L. G., Loera, L. J., Evoy, K. E., Renfro, M. L., Torrez, S. B., Zagorski, C. M., Perez, J. C., Jones, S. M., & Reveles, K. R. (2020). Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA. Addiction, 116(6), 1505–1511. https://doi.org/10.1111/add.15314
   Google Scholar
• Hogan, T. M., Olade, T. O., & Carpenter, C. R. (2014). A profile of acute care in an aging America: snowball sample identification and characterization of United States geriatric emergency departments in 2013. Academic Emergency Medicine: Official Journal of the Society for Academic Emergency Medicine, 21(3), 337–346. https://doi.org/10.1111/acem.12332
   PubMed Web of Science ®Google Scholar
• Huhn, A. S., & Dunn, K. E. (2017). Why aren’t physicians prescribing more buprenorphine? [Research Support, N.I.H., Extramural]. Journal of Substance Abuse Treatment, 78, 1–7. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medc&AN=28554597 https://doi.org/10.1016/j.jsat.2017.04.005
   PubMed Web of Science ®Google Scholar
• James, J. R., Gordon, L. M., Klein, J. W., Merrill, J. O., & Tsui, J. I. (2019). Interest in prescribing buprenorphine among resident and attending physicians at an urban teaching clinic. Substance Abuse, 40(1), 11–13. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=medp&AN=29578857 https://doi.org/10.1080/08897077.2018.1449176
   PubMed Web of Science ®Google Scholar
• Jasinski, D. R., Pevnick, J. S., & Griffith, J. D. (1978). Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Archives of General Psychiatry, 35(4), 501–516.
   PubMed Web of Science ®Google Scholar
• Johnson, R. E., Strain, E. C., & Amass, L. (2003). Buprenorphine: how to use it right. Drug and Alcohol Dependence, 70(2 Suppl), S59–S77.
   PubMed Web of Science ®Google Scholar
• Kamien, J. B. B., S, A., & Amass, L. (2008). Buprenorphine-naloxone versus methadone maintenance therapy: A randomised double-blind trial with opioid-dependent patients. Heroin Addiction and Related Clinical Problems, 10, 5–18.
   Web of Science ®Google Scholar
• Kissin, W., McLeod, C., Sonnefeld, J., & Stanton, A. (2006). Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence [Research Support, U.S. Gov’t, P.H.S.]. Journal of Addictive Diseases, 25(4), 91–103. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=17088229 https://doi.org/10.1300/J069v25n04_09
   PubMed Web of Science ®Google Scholar
• Légaré, F., Stacey, D., Brière, N., Fraser, K., Desroches, S., Dumont, S., Sales, A., Puma, C., & Aubé, D. (2013). Healthcare providers’ intentions to engage in an interprofessional approach to shared decision-making in home care programs: a mixed methods study. Journal of Interprofessional Care, 27(3), 214–222. https://doi.org/10.3109/13561820.2013.763777
   PubMed Web of Science ®Google Scholar
• Lofwall, M. R., & Walsh, S. L. (2014). A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. Journal of Addiction Medicine, 8(5), 315–326.
   PubMed Web of Science ®Google Scholar
• McCance‐Katz, E. F., Sullivan, L. E., & Nallani, S. (2010). Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. American Journal on Addictions, 19(1), 4–16. https://doi.org/10.1111/j.1521-0391.2009.00005.x
   PubMed Web of Science ®Google Scholar
• McMurphy, S., Shea, J., Switzer, J., & Turner, B. J. (2006). Clinic-based treatment for opioid dependence: a qualitative inquiry [Multicenter Study Research Support, Non-U.S. Gov’t]. American Journal of Health Behavior, 30(5), 544–554. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=16893317 https://doi.org/10.5993/AJHB.30.5.11
   PubMed Web of Science ®Google Scholar
• Molfenter, T., Fitzgerald, M., Jacobson, N., McCarty, D., Quanbeck, A., & Zehner, M. (2019). Barriers to buprenorphine expansion in Ohio: A time-elapsed qualitative study. Journal of Psychoactive Drugs, 51(3), 272–279.
   PubMed Web of Science ®Google Scholar
• Moore, B. A., Fiellin, D. A., Barry, D. T., Sullivan, L. E., Chawarski, M. C., O’Connor, P. G., & Schottenfeld, R. S. (2007). Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. Journal of General Internal Medicine, 22(4), 527–530. https://doi.org/10.1007/s11606-007-0129-0
   PubMed Web of Science ®Google Scholar
• Moore, B. A., Fiellin, D. A., Cutter, C. J., Buono, F. D., Barry, D. T., Fiellin, L. E., O’Connor, P. G., & Schottenfeld, R. S. (2016). Cognitive behavioral therapy improves treatment outcomes for prescription opioid users in primary care buprenorphine treatment. Journal of Substance Abuse Treatment, 71, 54–57. https://doi.org/10.1016/j.jsat.2016.08.016
   Google Scholar
• Moran, G., Snyder, C., Noftsinger, R., & Noda, J. (2017). Implementing medication-assisted treatment for opioid use disorder in rural primary care: Environmental scan. Rockville, MD: Agency for Healthcare Research and Quality.
   Google Scholar
• National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder. (2019). Medications for opioid use disorder save lives. M. Mancher & A. I. Leshner (Eds.). Washington, DC: The National Academies Press. https://doi.org/10.17226/25310
   Google Scholar
• National Institute of Health (NIH). (2020). The helping to end addiction long-termSM initiative. Retrieved January 8, 2020, from https://heal.nih.gov/
   Google Scholar
• Raisch, D. W., Fudala, P. J., Saxon, A. J., Walsh, R., Casadonte, P., Ling, W., Johnson, B. A., Malkerneker, U., Ordorica, P., Williford, W. O., & Sather, M. R. (2005). Pharmacists’ and technicians’ perceptions and attitudes toward dispensing buprenorphine/Naloxone to patients with opioid dependence. Journal of the American Pharmacists Association: JAPhA, 45(1), 23–32. https://doi.org/10.1331/1544345052843200
   PubMed Web of Science ®Google Scholar
• Ravitch, S. M., & Carl, N. M. (2015). Qualitative research: Bridging the conceptual, theoretical, and methodological. Sage Publications.
   Google Scholar
• Rev. (2019). Transcription for accurate academic research. Retrieved August 15, 2019, from https://www.rev.com/transcription-services/academic-research-transcription
   Google Scholar
• Riebl, S. K., MacDougal, C., Hill, C., Estabrooks, P. A., Dunsmore, J. C., Savla, J., Frisard, M. I., Dietrich, A. M., & Davy, B. M. (2016). A mixed methods analysis of beverage choices in adolescents and their parents using the theory of planned behavior. Journal of the Academy of Nutrition and Dietetics, 116(2), 226–239.e1. https://doi.org/10.1016/j.jand.2015.10.019
   PubMed Web of Science ®Google Scholar
• Schifter, D. E., & Ajzen, I. (1985). Intention, perceived control, and weight loss: an application of the theory of planned behavior. Journal of Personality and Social Psychology, 49(3), 843–851.
   PubMed Web of Science ®Google Scholar
• Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ (Clinical Research ed.), 357, j1550. https://doi.org/10.1136/bmj.j1550
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Administration. (2019). Providers clinical support system. Retrieved September 9, 2019, from https://pcssnow.org/
   Google Scholar
• Substance Abuse and Mental Health Services Administration. (2019a). Naltrexone. Retrieved February 24, 2019, from https://www.samhsa.gov/medication-assisted-treatment/treatment/naltrexone.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. (2019b). Practitioner and program data. Retrieved February 8, 2019, from https://www.samhsa.gov/programs-campaigns/medication-assisted-treatment/training-materials-resources/physician-program-data.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. (2020). September 28, 2018). Medication and counseling treatment. Retrieved December 11, 2019, from https://www.samhsa.gov/medication-assisted-treatment/treatment.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. (2021). Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21-07-01-003, NSDUH Series H-56). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved June 27 from https://www.samhsa.gov/data/
   Google Scholar
• Substance Abuse and Mental Health Services Administration. (2022). Become a Buprenorphine Waivered Practitioner. Retrieved June 27, from https://www.samhsa.gov/medication-assisted-treatment/become-buprenorphine-waivered-practitioner
   Google Scholar
• Thornton, J. D., Lyvers, E., Scott, V. G. G., & Dwibedi, N. (2017). Pharmacists’ readiness to provide naloxone in community pharmacies in West Virginia. Journal of the American Pharmacists Association: JAPhA, 57(2s), S12–S18.e14. https://doi.org/10.1016/j.japh.2016.12.070
   PubMedGoogle Scholar
• Tong, A., Sainsbury, P., & Craig, J. (2007). Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. International Journal for Quality in Health Care, 19(6), 349–357. https://doi.org/10.1093/intqhc/mzm042
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. (2018). 5-point strategy to combat the opioid crisis. Retrieved January 10, 2019, from https://www.hhs.gov/opioids/about-the-epidemic/hhs-response/index.html
   Google Scholar
• Volkow, N. D., Jones, E. B., Einstein, E. B., & Wargo, E. M. (2019). Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiatry, 76(2), 208-216. https://doi.org/10.1001/jamapsychiatry.2018.3126
   Google Scholar
• Webster, L., Gudin, J., Raffa, R. B., Kuchera, J., Rauck, R., Fudin, J., Adler, J., & Mallick-Searle, T. (2020). Understanding buprenorphine for use in chronic pain: expert opinion. Pain Medicine (Malden, MA), 21(4), 714–723. https://doi.org/10.1093/pm/pnz356
   PubMed Web of Science ®Google Scholar
• Zweben, J. E., & Payte, J. T. (1990). Methadone maintenance in the treatment of opioid dependence. A current perspective. The Western Journal of Medicine, 152(5), 588–599.
   PubMedGoogle Scholar